List of Excipients in Branded Drug MUCINEX D

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1075	ALUMINA
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1075	CARBOMER HOMOPOLYMER TYPE B
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1075	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1075	CI 15985
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1075	HYDROXYPROPYL METHYLCELLULOSE
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1075	MAGNESIUM STEARATE
A-S Medication Solutions	MUCINEX D	guaifenesin and pseudoephedrine hydrochloride	50090-1076	ALUMINUM OXIDE

Mucinex D Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: August 7, 2026

Mucinex D is an extended-release oral combination of guaifenesin and pseudoephedrine hydrochloride. The standard U.S. tablet contains 600 mg guaifenesin and 60 mg pseudoephedrine hydrochloride, administered every 12 hours. Its commercial differentiation depends on controlled release, tablet robustness, abuse-sensitive pseudoephedrine distribution, brand recognition, and compliance with the U.S. over-the-counter drug framework.

The strongest excipient opportunities are improved bilayer processing, smaller tablets, reproducible 12-hour release, lower manufacturing cost, and tamper-resistant designs. Mucinex D is an OTC product, so its principal barriers are formulation know-how, regulatory compliance, supply-chain control, and brand execution rather than current prescription-drug exclusivity.

What is Mucinex D and how is it formulated?

Mucinex D combines an expectorant with a nasal decongestant:

Attribute	Mucinex D
Active ingredients	Guaifenesin and pseudoephedrine hydrochloride
Strength per extended-release tablet	600 mg guaifenesin / 60 mg pseudoephedrine hydrochloride
Dosage form	Oral extended-release tablet
Dosing interval	Every 12 hours
Primary indications	Nasal congestion and chest congestion associated with the common cold
Regulatory category	U.S. OTC drug
Distribution issue	Pseudoephedrine products are subject to federal retail controls
Brand owner	Reckitt, through the Mucinex brand portfolio
Key formulation requirement	Sustained release of both active ingredients over approximately 12 hours

The product label identifies Mucinex D as an extended-release bilayer tablet. That architecture allows the manufacturer to manage two active ingredients with different dose levels, physical properties, and release requirements in one tablet [1].

Guaifenesin is present at a substantially higher mass than pseudoephedrine hydrochloride. The formulation therefore must control blend uniformity, layer weight, compression force, tablet hardness, and dissolution performance across two distinct drug-containing regions.

What excipients protect the commercial performance of Mucinex D?

The Mucinex D excipient strategy is designed around matrix formation, compression, flow, lubrication, and release control. Public labeling identifies inactive ingredients, but it does not disclose the full quantitative composition, manufacturing sequence, granulation parameters, or release-modeling data.

Functional excipient categories

Excipient function	Commercial purpose in an extended-release combination tablet
Hydrophilic matrix former	Controls water penetration and drug diffusion
Binder	Improves granule and tablet mechanical strength
Disintegrant	Controls structural breakup where rapid release is required
Filler	Adjusts tablet mass, compressibility, and manufacturability
Glidant	Improves powder flow and die filling
Lubricant	Reduces sticking and ejection force
Film-coating system	Improves swallowability, appearance, identification, and environmental protection
Opacifier or colorant	Supports product identification and brand consistency

The critical technical issue is balancing sustained release against acceptable tablet size. Guaifenesin contributes most of the active mass, while pseudoephedrine must remain evenly distributed and release within the intended pharmacokinetic window.

A formulation that relies heavily on hydrophilic polymers can produce a large tablet, slow dissolution excessively, or create sensitivity to compression force. A formulation with insufficient matrix strength can release pseudoephedrine too quickly after hydration or mechanical damage.

How does a bilayer tablet improve Mucinex D performance?

A bilayer tablet can separate formulation functions within one unit dose. One layer can be optimized for guaifenesin loading and release, while the second layer can manage the lower-dose pseudoephedrine component.

The principal benefits are:

1. Reduced risk of direct incompatibility between the two active ingredients.
2. Independent control of layer composition and drug loading.
3. Better control of content uniformity for pseudoephedrine.
4. Greater flexibility in tuning dissolution profiles.
5. Potentially lower total excipient burden than a single homogeneous matrix.

The main manufacturing risks are layer adhesion, cross-contamination between layers, weight variation, capping, lamination, and inconsistent compression at the layer interface. Commercial-scale production requires tight control of feeder behavior and powder segregation.

Manufacturing parameters with the highest IP value

The most defensible formulation and process know-how is likely to reside in:

• Polymer grade and viscosity selection.
• Active-to-polymer ratios.
• Granulation solvent and endpoint.
• Particle-size distribution for both active ingredients.
• Layer compression sequence.
• Interfacial bonding conditions.
• Lubricant concentration and mixing time.
• Coating weight gain.
• Dissolution specifications at multiple pH conditions.
• Packaging controls for humidity and mechanical stress.

These parameters can be protected through trade secrets even when the underlying ingredients are generic.

What formulation patents protect Mucinex D?

Mucinex D is an OTC combination product, and its commercial protection should be analyzed differently from a prescription drug with an active Orange Book patent estate.

Orange Book status

Mucinex D is not typically evaluated as a conventional prescription NDA product with a publicly listed Orange Book patent-and-exclusivity profile. OTC products may be marketed under an FDA OTC monograph, an approved application, or another applicable regulatory pathway. The absence of a conventional Orange Book listing does not eliminate formulation or process IP, but it changes the generic-entry analysis.

FDA’s OTC framework addresses active ingredients, concentrations, indications, labeling, and dosage forms. Guaifenesin and oral nasal decongestants such as pseudoephedrine are addressed under FDA OTC drug regulations and related monograph rules [2].

Patent categories relevant to the product

Potentially relevant patent families include:

Patent category	Relevance to Mucinex D
Extended-release matrix patents	Control guaifenesin and pseudoephedrine release
Bilayer-tablet patents	Protect spatial separation and layer manufacturing
Combination-product patents	Cover co-formulation of expectorant and decongestant
Coating patents	Protect environmental or mechanical release controls
Manufacturing patents	Cover granulation, compression, and coating processes
Abuse-deterrence patents	May address pseudoephedrine extraction or tampering
Packaging patents	Address moisture protection, child resistance, or unit dosing

Public product labeling does not establish that any particular formulation patent remains enforceable. Patent term, ownership, continuation practice, terminal disclaimers, maintenance fees, and claim scope must be assessed in the relevant jurisdiction.

When does Mucinex D lose exclusivity?

Mucinex D has no single prescription-style loss-of-exclusivity date that controls all market entry. The product’s commercial exclusivity is a combination of brand rights, formulation know-how, regulatory compliance, retail placement, and pseudoephedrine controls.

The relevant market-entry timeline is:

Event	Commercial effect
Launch of OTC combination product	Establishes brand and retail presence
Expiration of applicable formulation patents	Removes enforceable patent barriers, if any remain
Availability of compliant OTC alternatives	Creates direct substitution risk
Private-label adoption	Increases price pressure
Retail substitution or store-brand expansion	Weakens branded shelf advantage
Reformulation or packaging change	May create new, narrow protection opportunities

A competing manufacturer generally does not need to copy the Mucinex D formulation. It can develop a different excipient system that meets the same release and labeling requirements. That makes freedom-to-operate analysis more important than identifying a single blocking patent.

Are Paragraph IV challenges relevant to Mucinex D?

Paragraph IV litigation is principally associated with abbreviated new drug applications and listed drugs subject to the Hatch-Waxman framework. It is not the default market-entry mechanism for every OTC monograph product.

For an OTC product such as Mucinex D, a competitor may pursue:

• An OTC monograph-compliant product.
• An approved application route where applicable.
• A private-label or store-brand product.
• A different formulation with the same active ingredients and indications.
• A product marketed under a separate trade name.

A Paragraph IV challenge could become relevant if a competitor relies on an approved listed drug and files an ANDA containing a patent certification. That question depends on the regulatory history of the specific product and the patents listed for the relevant reference product. Public labeling alone does not establish a current Paragraph IV dispute.

What FDA regulatory issues affect Mucinex D competitors?

A competing product must satisfy requirements for both active ingredients and the finished dosage form. Key issues include:

• Correct active-ingredient strength.
• Acceptable extended-release performance.
• Appropriate labeling for nasal and chest congestion.
• Contraindications and warnings for pseudoephedrine.
• Manufacturing under current good manufacturing practice.
• Stability through the labeled shelf life.
• Dissolution testing that demonstrates consistent release.
• Control of impurities and degradation products.
• Child-resistant packaging where required.
• Compliance with pseudoephedrine sales restrictions.

Pseudoephedrine also creates a distribution barrier. The Combat Methamphetamine Epidemic Act imposes purchase limits, identification requirements, sales-log obligations, and retail controls for pseudoephedrine products [3]. That compliance burden affects wholesalers, pharmacies, online sellers, and private-label manufacturers.

What excipient strategies create commercial opportunities?

Smaller-tablet reformulation

A high-value opportunity is reducing tablet size without compromising 12-hour release. This could involve higher-efficiency matrix polymers, optimized granulation, co-processed excipients, or improved active particle engineering.

Smaller tablets can improve swallowing, reduce packaging volume, and lower shipping costs. The principal risk is an altered dissolution profile or dose dumping after tablet damage.

Robust bilayer processing

Manufacturers can compete through a more reliable bilayer process that reduces layer separation and weight variation. A robust design may lower scrap rates and improve high-speed compression performance.

This opportunity is especially relevant for contract manufacturers and private-label suppliers that need to match branded-product dissolution without duplicating its exact composition.

Abuse-sensitive formulations

Pseudoephedrine is regulated because it can be diverted for illicit methamphetamine production. A formulation that makes extraction more difficult could support a differentiated product, although the commercial value depends on regulatory acceptance, consumer handling, and manufacturing cost.

Possible approaches include stronger matrix systems, coating structures, or formulations that reduce recovery of pseudoephedrine from crushed tablets. These approaches require careful testing because excessive matrix strength can impair therapeutic release.

Improved moisture and temperature stability

A moisture-resistant coating, high-barrier blister, or optimized bottle-and-desiccant system can reduce dissolution drift and tablet softening. Stability is commercially important for nationwide distribution, warehouse storage, and seasonal demand spikes.

Lower-cost excipient systems

A private-label manufacturer can pursue a lower-cost formulation using widely available compendial excipients, fewer processing steps, and a simplified coating system. The commercial objective is not to reproduce the Mucinex D brand but to achieve comparable therapeutic performance at a lower unit cost.

Alternative dosage forms

Potential extensions include:

• Smaller tablets.
• Unit-dose blister formats.
• Liquid or suspension products, where technically and regulatorily feasible.
• Fast-dissolving products for guaifenesin-only use.
• Separate expectorant and decongestant products.
• Extended-release products with different dosing intervals.

The combination of pseudoephedrine restrictions and consumer preference may make separate-product strategies more practical than a new combination product in some retail channels.

Which companies are challenging Mucinex D commercially?

The competitive field includes branded OTC manufacturers, national retailers, pharmacy chains, and generic-label suppliers. Competition is generally based on price, shelf placement, packaging, active-ingredient equivalence, and seasonal promotion.

Relevant competitor groups include:

Competitor group	Competitive approach
National OTC brands	Brand trust and broad retail distribution
Store brands	Lower price and retailer control
Generic manufacturers	Ingredient and dosage-form substitution
E-commerce sellers	Convenience and multipack pricing
Combination-cold-product brands	Cross-selling within seasonal cough-and-cold portfolios
Guaifenesin-only brands	Avoid pseudoephedrine restrictions and broaden access

Mucinex D’s strongest commercial defense is brand familiarity combined with a recognizable 12-hour format. Its main vulnerability is substitution by lower-priced products using the same active ingredients or by separate products that satisfy the consumer’s symptoms.

What is the revenue exposure from Mucinex D competition?

Mucinex D revenue is exposed to several factors:

• Seasonal respiratory illness.
• Retailer promotion and shelf allocation.
• Store-brand price discounts.
• Pseudoephedrine purchase restrictions.
• Stock availability during demand surges.
• Consumer movement toward single-symptom products.
• Private-label manufacturing capacity.
• Price elasticity in the OTC category.

The product’s revenue is not protected by prescription reimbursement or physician prescribing. Consumers and retailers can switch products rapidly when active ingredients, strength, and dosing frequency are comparable.

For an excipient supplier, the addressable opportunity is broader than Mucinex D alone. A successful release-control platform could be adapted to guaifenesin-only products, pseudoephedrine combinations, dextromethorphan combinations, antihistamine products, and other seasonal OTC tablets.

How strong is the Mucinex D patent estate?

The commercial patent estate is best characterized as moderate for formulation know-how and weaker as a stand-alone exclusivity barrier, unless unexpired claims specifically cover the marketed bilayer composition or manufacturing process.

Protection type	Relative commercial strength
Brand name and trade dress	High against confusingly similar branding
OTC regulatory compliance	Moderate
Exact formulation patent claims	Potentially high if unexpired and technically read on the product
Broad extended-release excipient claims	Usually vulnerable to design-around
Manufacturing trade secrets	Potentially high but difficult to detect and enforce
Pseudoephedrine distribution controls	High operational barrier, not product exclusivity
Retail relationships	High commercially, outside patent law

A competitor can reduce litigation risk by selecting different polymers, changing the layer architecture, using a distinct coating system, and validating an independent dissolution profile.

What litigation or settlements affect Mucinex D?

No current litigation or settlement should be treated as a controlling barrier without a product-specific review of federal court dockets, Patent Trial and Appeal Board records, FDA regulatory files, and patent assignments.

For commercial diligence, the relevant questions are:

• Whether an unexpired patent claims the marketed bilayer tablet.
• Whether the patent owner has sued generic or private-label entrants.
• Whether any settlement restricts launch timing.
• Whether a patent has been invalidated, disclaimed, or abandoned.
• Whether a competitor’s formulation was designed around the asserted claims.
• Whether trade-secret claims concern manufacturing or release testing.

A litigation search should cover Reckitt, Mucinex, guaifenesin, pseudoephedrine hydrochloride, extended-release bilayer tablets, and related assignees.

Key Takeaways

• Mucinex D is a 600 mg guaifenesin/60 mg pseudoephedrine hydrochloride extended-release bilayer tablet.
• The primary formulation challenge is controlling two active ingredients with different dose levels and release requirements.
• High-value excipient opportunities include smaller tablets, stronger layer adhesion, improved moisture stability, lower-cost matrices, and tamper-resistant designs.
• Mucinex D is an OTC product, so market entry is not governed solely by a conventional Orange Book exclusivity timeline.
• Paragraph IV analysis depends on the product’s specific regulatory pathway and any listed patents.
• Pseudoephedrine distribution controls create an operational barrier for competitors but do not provide conventional product exclusivity.
• The strongest defensible IP may reside in narrow formulation claims, manufacturing parameters, dissolution specifications, and trade secrets.
• Private-label and store-brand products pose the clearest commercial threat because they can use compliant alternative excipient systems.
• An excipient platform developed for Mucinex D can be extended to other extended-release OTC cough-and-cold combinations.

FAQs

Can a generic manufacturer copy the Mucinex D excipients?

It can use the same or different excipients if the resulting product complies with applicable FDA requirements and does not infringe enforceable patent claims. Exact quantitative composition and process conditions are not disclosed on the consumer label.

Is Mucinex D protected by an Orange Book patent?

Mucinex D is generally analyzed as an OTC product rather than as a conventional prescription NDA with a standard Orange Book patent listing. The relevant protection may instead involve OTC regulatory status, formulation patents, trade secrets, and branding.

What is the best excipient for extending guaifenesin release?

No single excipient is universally optimal. Hydrophilic matrix polymers are common candidates, but the selection depends on polymer grade, tablet geometry, compression force, particle size, and the target dissolution profile.

Does pseudoephedrine require a special formulation?

Pseudoephedrine does not necessarily require a special excipient system, but its distribution is subject to federal controls. A formulation containing pseudoephedrine must also meet applicable stability, dissolution, labeling, and manufacturing requirements.

Is a Mucinex D private-label product commercially attractive?

Yes. The opportunity is strongest where a manufacturer can achieve comparable 12-hour release, reduce tablet or packaging cost, and secure retail distribution. The main constraints are seasonal demand, pseudoephedrine compliance, quality control, and retailer pricing pressure.

References

1. DailyMed. (n.d.). Mucinex D extended-release tablets: Guaifenesin and pseudoephedrine hydrochloride labeling. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs and applicable regulations for cough, cold, allergy, bronchodilator, and antiasthmatic drug products. FDA.

3. U.S. Drug Enforcement Administration. (n.d.). Pseudoephedrine and ephedrine retail sales requirements under the Combat Methamphetamine Epidemic Act. U.S. Department of Justice.